Funder
National Medical Research Council
Pfizer
Astellas Pharma US
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Teo JQ, Candra SR, Lee SJ, Chia SY, Leck H, Tan AL, Neo HP, Leow KW, Cai Y, Ee RP, et al. Candidemia in a major regional tertiary referral hospital - epidemiology, practice patterns and outcomes. Antimicrob Resist Infect Control. 2017;6:27.
2. Shields RK, Nguyen MH, Press EG, Kwa AL, Cheng S, Du C, Clancy CJ. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56(9):4862–9.
3. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement. CLSI document M27-S4. Wayne: Clinical and Laboratory Standards Institute; 2012.
4. Canton E, Peman J, Iniguez C, Hervas D, Lopez-Hontangas JL, Pina-Vaz C, Camarena JJ, Campos-Herrero I, Garcia-Garcia I, Garcia-Tapia AM, et al. Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol. 2013;51(8):2691–5.
5. Vandeputte P, Larcher G, Berges T, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother. 2005;49(11):4608–15.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献